Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Phase 3

Terminated

Conditions: Advanced BRAFV600 Wild-type Melanoma

Interventions: Drug: Cobimetinib
Drug: Pembrolizumab
Drug: Atezolizumab

First Posted Date: 2017-09-06

Last Posted Date: 2022-09-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 446

Registration Number: NCT03273153

Locations: 🇺🇸
USC Norris Cancer Center; USC Oncology Hematology Newport Beach, Newport Beach, California, United States
🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 118 locations

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Phase 2

Completed

Conditions: Beta-Thalassemia

Interventions: Drug: Bitopertin

First Posted Date: 2017-09-05

Last Posted Date: 2018-10-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT03271541

Locations: 🇮🇹
Ospedale Maggiore di Milano; Cardio-Metabolic Diseases, Milano, Lombardia, Italy
🇹🇭
Siriraj Hospital; Division of Haematology-Oncology, Bangkok Noi, Thailand
🇱🇧
Chronic Care Center, Baabda, Lebanon

and more 1 locations

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Alectinib

First Posted Date: 2017-09-05

Last Posted Date: 2022-11-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 355

Registration Number: NCT03271554

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of

and more 33 locations

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Phase 2

Completed

Conditions: Solid Tumors

Interventions: Drug: Cobimetinib
Drug: Atezolizumab Cohort 7
Drug: Atezolizumab

First Posted Date: 2017-08-28

Last Posted Date: 2021-05-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 87

Registration Number: NCT03264066

Locations: 🇧🇪
AZ Groeninge, Kortrijk, Belgium
🇭🇺
Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 16 locations

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

Not Applicable

Completed

Conditions: Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease

Interventions: Other: Spirometry
Other: Accelerometry
Other: 6MWT

First Posted Date: 2017-08-24

Last Posted Date: 2021-03-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 178

Registration Number: NCT03261037

Locations: 🇮🇹
A.O.U. S. Luigi Gonzaga; Interstiziopatie Malattie Rare Polmone, Orbassano (to), Piemonte, Italy
🇫🇷
Hopital Cote De Nacre; Pneumologie, Caen, France
🇫🇷
Hopital de Pontchaillou; Service de Pneumologie, Rennes, France

and more 34 locations

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Phase 1

Completed

Conditions: Diffuse Large B-cell Lymphoma
High-Grade B-cell Lymphoma

Interventions: Drug: RO6870810
Drug: Venetoclax
Drug: Rituximab

First Posted Date: 2017-08-21

Last Posted Date: 2022-01-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 39

Registration Number: NCT03255096

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇦🇺
Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia

and more 6 locations

Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Gantenerumab

First Posted Date: 2017-08-02

Last Posted Date: 2018-12-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 114

Registration Number: NCT03236844

Locations: 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
🇺🇸
PRA, Marlton, New Jersey, United States
🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Completed

Conditions: Small Cell Lung Carcinoma
Carcinoma, Non-Small Cell Lung
Triple Negative Breast Carcinoma
Hepatocellular Carcinoma
Urothelial Carcinoma

Interventions: Drug: Atezolizumab

First Posted Date: 2017-07-28

Last Posted Date: 2022-08-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1758

Registration Number: NCT03232593

Locations: 🇰🇷
Dongnam Inst.of Radiological & Medical Sciences, Busan, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Inje university Haeundae Paik Hospital, Busan, Korea, Republic of

and more 52 locations

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ipatasertib
Drug: Itraconazole

First Posted Date: 2017-07-19

Last Posted Date: 2017-11-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15

Registration Number: NCT03222310

Locations: 🇺🇸
Covance Research Unit - Dallas, Dallas, Texas, United States

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: RO7049665
Biological: Placebo

First Posted Date: 2017-07-18

Last Posted Date: 2019-08-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT03221179

Locations: 🇳🇱
PRA Health Sciences Early Development Services, Zuidlaren, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy